Is It Time to Buy Amgen, Inc.'s Stock?

Amgen has plenty of potentially positive catalysts on the horizon as well as a number of headwinds. Find out which side is the likeliest to prevail.

Sep 3, 2014 at 9:01AM

It's taken more than a decade, but the past couple of years have brought with them mostly cheers and very few jeers for Amgen (NASDAQ:AMGN) shareholders. As you can see below, after spending more than a decade stuck in a trading range, Amgen's stock has exploded higher over the past three years.

AMGN Chart

AMGN data by YCharts

But, can Amgen sustain these gains and head even higher? I intend to answer this question today to the best of my ability given both the positive catalysts and negative headwinds currently facing the company.

Of course, before I proceed I think it's only fair to mention that just because I'm taking a stance on where Amgen could head next that it doesn't mean I won't be wrong. The reason we have a stock market in the first place is because there are two sides to every trade, and you should make sure to weigh both before deciding to invest in Amgen.

Amgen by the numbers
In the vast majority of cases, looking at statistical comparisons of biopharmaceutical companies won't make a lot of sense, especially considering that many are in the clinical stage of their development and most don't have consistent revenue, cash flow, or profits. In Amgen's case, however, the company is a well-established biotech giant, so it can give us important valuation insight to compare Amgen to some of its closest peers.

Here are some of the important metrics about Amgen and its peers that you need to know:


Forward P/E Ratio

Projected Five-Year Growth Rate

Profit Margin (TTM)

Dividend Yield






Johnson & Johnson (NYSE:JNJ)





Novartis (NYSE:NVS)





Teva Pharmaceutical (NYSE:TEVA)





Source: Yahoo! Finance, TTM = trailing 12 months.

As you can see above, there are some marked differences in a few categories between Amgen and its peers. If you're wondering why I chose these companies, it's because Teva competes against Amgen in the cancer therapeutic support space, Johnson & Johnson's Remicade is a huge competitor to Amgen's Enbrel, and Novartis because it offers both a broad-ranging branded products portfolio, but also owns a generic subsidiary known as Sandoz which could be a major threat to Amgen's best-selling sister drugs, Neulasta/Neupogen.

Based on the projected growth rate of these companies Amgen looks like a clear winner. In the defense of Johnson & Johnson and Novartis, Amgen is comparably smaller, so growth may come to it a bit easier. Not to mention, as Amgen's management noted during its conference call, the company is on pace to present late-stage data on 10 compounds before the end of 2016. These late-stage catalysts present a bounty of growth opportunity for Amgen.

Profit margins for Amgen are also significantly higher. I would attribute this to the company's stringent cost-cutting in the wake of its expensive late-stage studies and forecasted drug launches. Amgen announced last quarter that it plans to let anywhere between 12% and 15% of its nearly 20,000 employees go in order to reduce capital expenditures by $700 million (based on what those salaries and projects cost in 2013). These funds will help offset the higher costs of late-stage clinical studies and drug launches. As Amgen's "binary bonanza" takes shape, it's possible higher costs from Food and Drug Administration filing to marketing costs could weigh on its margins a bit. 

Amgen Q2 earnings call presentation slide. Source: Amgen.

However, you'll note that Amgen's dividend yield is the lowest in the pack. This isn't necessarily a bad thing as Johnson and Johnson's 52-year streak of boosting its dividend and Novartis' broad portfolio afford investors in these stocks the expectation of above-average payouts. Amgen, though, has been steadily buying back its own shares for many years. Since 2004, it's reduced its outstanding share count by more than 40%, which helps to boost its EPS. In other words, shareholders aren't exactly getting the short end of the stick holding Amgen.

Finally, you'll note that Teva is arguably the least expensive of all four of these names on the basis of forward P/E. I'd remind investors, though, that Teva's multiple sclerosis drug Copaxone is closing in on its patent exclusivity loss in the coming months, and it was responsible for close to one-fifth of Teva's total revenue last quarter, so perhaps this lower valuation for Teva makes sense.

Is Amgen a buy?
Now that you have a better idea of how Amgen compares with its peers on the surface, let's get back to our initial question: Is it time to buy Amgen's stock?

My answer is "No," and I'll explain why.


Deutsche Bank Health Conference presentation. Source: Amgen.

To begin with, I worry about Amgen's ability to turn its buyout of Onyx Pharmaceuticals into a positive. Paying $10.4 billion for Onyx was arguably expensive, and multiple myeloma drug Kyprolis could face more challenges than expected when it comes to expanding its label from just a third-line indication to a second-line treatment.

On the plus side, the ASPIRE late-stage study demonstrated a statistically significant 8.7 month progression-free survival advantage for Kyprolis compared to the control arm. However, Kyprolis didn't meet its primary endpoint of improving overall survival in the FOCUS study released just over a week later. The concern this raises is that the European Medicines Agency in Europe and the Food and Drug Administration in the U.S. may not be as willing to approve Kyrpolis' label expansion if it doesn't help patients live longer. If Kyprolis struggles to hit Wall Street annual peak sales projection of $2 billion to $3 billion, Amgen's purchase of Onyx may be looked upon with disdain from shareholders rather than cheers years down the road.

Secondly, I worry about Amgen's ability to grow while cutting staff. I fully understand the cost constraints that 10 late-stage studies and potential new drug or supplemental drug filings can bring about, but it's very difficult to grow a business by shrinking its workforce. Turning to cost-cutting and share buybacks has been a common tactic employed by Amgen's management team throughout the years in order to give investors the perception that its business is growing healthfully. Underneath those cost cuts and share buybacks, however, is a company that's struggled to grow revenue at a rate that would please its stakeholders.

Finally, Amgen's going to be potentially walloped by the expiration of Neulasta's patent in the U.S. in late 2015. This drug, which helps patients maintain their white blood cell counts and avoid infections while undergoing chemotherapy, brought in $895 million of Amgen's $3.76 billion in total U.S. sales in the second quarter. Even if Amgen delivers some positive news to investors with its late-stage pipeline push, it'll be hard-pressed to make up for what I suspect could be $2 billion in lost annual revenue, if not more, in 2016 alone.

All things considered, Amgen isn't a bad company by any means, but I wouldn't chase its stock any higher here.

Amgen's late-stage pipeline may offer plenty of potential, but this technological revolution could leave Amgen eating dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Johnson & Johnson. It also recommends Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers